CerS2 is a druggable target in triple-negative breast cancer
Hissah Alatawi, Nair Hariprasad Haritha, Lingbao Ai, Iqbal Mahmud, Abhishek Gour, Amandeep Singh, Doohyun Baek, Bowen Yan, Chandra Kumar Maharjan, Weizhou Zhang, Brian Keith Law, Maria Zajac‐Kaye, Chris D. Vulpe, Olga A. Guryanova, Arun Kumar Sharma, , Satya Narayan
This paper identifies DH20931 as a first-in-class agonist of CerS2 that induces ER stress and apoptosis in TNBC cells, showing preclinical efficacy.
Molecular Cancer Therapeutics · Apr 17, 2026Peer-reviewedCancer Biology